---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-043545"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2023-05-26T23:59:59+00:00"
generated_at: "2026-06-14T12:34:16.882326+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma receives Nasdaq deficiency letter for low stockholders' equity

## Summary
- Stockholders' equity of $1.73M as of March 31, 2023, below Nasdaq's $2.5M minimum.
- Company has until July 10, 2023 to submit compliance plan; possible extension to Dec 11, 2023.
- No immediate effect on trading; common stock continues on Nasdaq under symbol ABVC.

## SEC filing metadata
- accession: 0001213900-23-043545
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2023-05-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390023043545/0001213900-23-043545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390023043545/ea179215-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-043545
- JSON: https://secwatch.observer/filing/0001213900-23-043545.json
- Plain text: https://secwatch.observer/filing/0001213900-23-043545.txt

## Key facts
- Listing & Compliance Notices
  ABVC BIOPHARMA, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2,500,000, and the Company’s stockholders’ equity was $1,734,507 as of March 31, 2023. In accordance with Nasdaq rules, the Company has 45 calendar days, or until July 10, 2023, to submit a plan to regain compliance. If the plan is accepted,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390023043545/0001213900-23-043545-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.